Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence  Christian Toso, Gilles Mentha, Pietro Majno  Journal of Hepatology  Volume 59, Issue 1, Pages 3-5 (July 2013) DOI: 10.1016/j.jhep.2013.03.029 Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Proposed management of patients with post-transplant HCC recurrence. mTOR, mammalian target-of-rapamycin; RFA, radiofrequency ablation; TACE, transarterial chemo-embolization; TARE, transarterial radio-embolization. ∗Treatment invasiveness should be modulated according to the expected outcome: late recurrences have better potential outcomes and may warrant more aggressive approaches. ∗∗Alone or combined to hepatic HCC recurrence. Journal of Hepatology 2013 59, 3-5DOI: (10.1016/j.jhep.2013.03.029) Copyright © 2013 European Association for the Study of the Liver Terms and Conditions